Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a
- PDF / 1,183,007 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 28 Downloads / 206 Views
UROGENITAL
Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study T. Ullrich 1,2 & C. Arsov 3 & M. Quentin 1 & F. Mones 1 & A. C. Westphalen 2 & D. Mally 3 & A. Hiester 3 & P. Albers 3 & G. Antoch 1 & L. Schimmöller 1 Received: 2 February 2020 / Revised: 31 March 2020 / Accepted: 29 May 2020 # The Author(s) 2020
Abstract Objectives To assess the ability of multiparametric MRI (mp-MRI) of the prostate to exclude prostate cancer (PCa) progression during monitoring patients on active surveillance (AS). Methods One hundred forty-seven consecutive patients on AS with mp-MRI (T2WI, DWI, DCE-MRI) at 3T were initially enrolled. Fifty-five received follow-up mp-MRI after a minimum interval of 12 months and subsequent targeted MR/US fusionguided biopsy (FUS-GB) plus concurrent systematic transrectal ultrasound-guided (TRUS-GB) biopsy as reference standard. Primary endpoint was the negative predictive value (NPV) of the follow-up mp-MRI to exclude histopathologic tumor progression using PRECISE recommendations. Secondary endpoints were the positive predictive value (PPV), sensitivity, specificity, Gleason score (GS) upgrades, and comparison of biopsy method. Results Of 55 patients, 29 (53%) had a GS upgrade on re-biopsy. All 29 patients showed a tumor progression on follow-up mpMRI. Fifteen of 55 patients (27%) displayed signs of tumor progression, but had stable GS on re-biopsy. None of the 11 patients (20%) without signs of progression on follow-up mp-MRI had a GS upgrade on re-biopsy. The NPV was 100%, PPV was 66%, sensitivity was 100%, and specificity 42%. FUS-GB resulted in GS upgrade significantly more often (n = 28; 51%) compared with TRUS-GB (n = 12; 22%; p < 0.001). Conclusions (Follow-up) Mp-MRI can reliably exclude PCa progression in patients on AS. Standard serial re-biopsies might be waived if follow-up mp-MRIs are stable. Over 60% of patients with signs of tumor progression on mp-MRI during AS had a GS upgrade on re-biopsy. Targeted re-biopsies should be performed if cancer progression or higher-grade PCa is suspected on mp-MRI. Key Points • None of the patients with unsuspicious mp-MRI had a GS upgrade in re-biopsy and mp-MRI might replace serial biopsies in these cases • More than 60% of patients with mp-MRI signs of tumor progression had subsequent Gleason score (GS) upgrades • Targeted re-biopsies should be performed in case of higher GS cancer suspicion on mp-MRI Keywords Magnetic resonance imaging . Prostate cancer . Early diagnosis . Imaging-guided biopsy . Assessment . risk
* C. Arsov [email protected] 1
Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, 40225 Dusseldorf, Germany
2
Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave, M-392, San Francisco, CA 94143-0628, USA
3
Medical Faculty, Department of Urology, University Dusseldorf, Moorenstr. 5, 40225 Dusseldorf, Germany
Abbreviat
Data Loading...
